These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2803920)

  • 21. Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation.
    Langers P; Cremers SC; den Hartigh J; Rijnbeek EM; Ringers J; Lamers CB; van Hoek B
    Aliment Pharmacol Ther; 2005 Mar; 21(5):549-57. PubMed ID: 15740538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin.
    Miller AA; Schmidt CG
    Cancer Res; 1987 Mar; 47(5):1461-5. PubMed ID: 3815348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
    Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
    Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maximum a posteriori Bayesian estimation of epirubicin clearance by limited sampling.
    Ralph LD; Thomson AH; Dobbs NA; Twelves C
    Br J Clin Pharmacol; 2004 Jun; 57(6):764-72. PubMed ID: 15151522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
    Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
    Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Populational pharmacokinetics of doxorubicin applied to personalised its dosing in cancer patients].
    Escudero-Ortiz V; Ramón-López A; Duart MA; Pérez-Ruixo JJ; Valenzuela B
    Farm Hosp; 2012; 36(4):282-91. PubMed ID: 22129650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation.
    Saint-Marcoux F; Debord J; Undre N; Rousseau A; Marquet P
    Ther Drug Monit; 2010 Apr; 32(2):129-35. PubMed ID: 20110850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
    Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
    Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study.
    Freyer G; Tranchand B; Ligneau B; Ardiet C; Souquet PJ; Court-Fortune I; Riou R; Rebattu P; Boissel JP; Trillet-Lenoir V; Girard P
    Br J Clin Pharmacol; 2000 Oct; 50(4):315-24. PubMed ID: 11012554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Constant infusion schedule for adriamycin: a phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system.
    Lokich J; Bothe A; Zipoli T; Green R; Sonneborn H; Paul S; Philips D
    J Clin Oncol; 1983 Jan; 1(1):24-8. PubMed ID: 6668481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bayesian calculation of methotrexate clearance after low dose intramuscular administration in patients with rheumatoid arthritis.
    Monjanel-Mouterde S; Lafforgue P; Blanc A; Catalin J; Aquaviva PC; Durand A
    J Rheumatol; 1998 Jul; 25(7):1276-81. PubMed ID: 9676756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New sampling strategy using a Bayesian approach to assess iohexol clearance in kidney transplant recipients.
    Benz-de Bretagne I; Le Guellec C; Halimi JM; Gatault P; Barbet C; Alnajjar A; Büchler M; Lebranchu Y; Andres CR; Vourcʼh P; Blasco H
    Ther Drug Monit; 2012 Jun; 34(3):289-97. PubMed ID: 22585184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
    Buzzoni R; Bonadonna G; Valagussa P; Zambetti M
    J Clin Oncol; 1991 Dec; 9(12):2134-40. PubMed ID: 1960555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bayesian estimation of a cancer population by capture-recapture with individual capture heterogeneity and small sample.
    Bailly L; Daurès JP; Dunais B; Pradier C
    BMC Med Res Methodol; 2015 Apr; 15():39. PubMed ID: 25902941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol.
    Leca F; Marchiset-Leca D; Noble A; Antonetti M
    Eur J Drug Metab Pharmacokinet; 1991; 16(2):107-11. PubMed ID: 1936069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.
    Djebli N; Rousseau A; Hoizey G; Rerolle JP; Toupance O; Le Meur Y; Marquet P
    Clin Pharmacokinet; 2006; 45(11):1135-48. PubMed ID: 17048977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma.
    Rousseau A; Sabot C; Delepine N; Delepine G; Debord J; Lachâtre G; Marquet P
    Clin Pharmacokinet; 2002; 41(13):1095-104. PubMed ID: 12403645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration.
    Salinger DH; Vicini P; Blough DK; O'Donnell PV; Pawlikowski MA; McCune JS
    J Clin Pharmacol; 2010 Nov; 50(11):1292-300. PubMed ID: 20075185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.